BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

253 related articles for article (PubMed ID: 15468339)

  • 1. Stability of leukemia-associated aberrant immunophenotypes in patients with acute myeloid leukemia between diagnosis and relapse: comparison with cytomorphologic, cytogenetic, and molecular genetic findings.
    Voskova D; Schoch C; Schnittger S; Hiddemann W; Haferlach T; Kern W
    Cytometry B Clin Cytom; 2004 Nov; 62(1):25-38. PubMed ID: 15468339
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Detection of minimal residual disease in unselected patients with acute myeloid leukemia using multiparameter flow cytometry for definition of leukemia-associated immunophenotypes and determination of their frequencies in normal bone marrow.
    Kern W; Danhauser-Riedl S; Ratei R; Schnittger S; Schoch C; Kolb HJ; Ludwig WD; Hiddemann W; Haferlach T
    Haematologica; 2003 Jun; 88(6):646-53. PubMed ID: 12801840
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The impact of cell heterogeneity and immunophenotypic changes on monitoring minimal residual disease in acute myeloid leukemia.
    Zelezníková T; Babusíková O
    Neoplasma; 2006; 53(6):500-6. PubMed ID: 17167719
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Multiparametric analysis of normal and postchemotherapy bone marrow: Implication for the detection of leukemia-associated immunophenotypes.
    Olaru D; Campos L; Flandrin P; Nadal N; Duval A; Chautard S; Guyotat D
    Cytometry B Clin Cytom; 2008 Jan; 74(1):17-24. PubMed ID: 18061947
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Leukemia-associated aberrant immunophenotype in patients with acute myeloid leukemia: changes at refractory disease or first relapse and clinicopathological findings.
    Cui W; Zhang D; Cunningham MT; Tilzer L
    Int J Lab Hematol; 2014 Dec; 36(6):636-49. PubMed ID: 24602197
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comprehensive flow cytometry phenotype in acute leukemia at diagnosis and at relapse.
    Li X; Du W; Liu W; Li X; Li H; Huang SA
    APMIS; 2010 May; 118(5):353-9. PubMed ID: 20477810
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Leukemia-associated immunophenotypes subdivided in "categories of specificity" improve the sensitivity of minimal residual disease in predicting relapse in acute myeloid leukemia.
    Rossi G; Giambra V; Minervini MM; De Waure C; Mancinelli S; Ciavarella M; Sinisi NP; Scalzulli PR; Carella AM; Cascavilla N
    Cytometry B Clin Cytom; 2020 May; 98(3):216-225. PubMed ID: 31697027
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Increased myeloid precursors in regenerating bone marrow; implications for detection of minimal residual disease in acute myeloid leukemia.
    Zeleznikova T; Stevulova L; Kovarikova A; Babusikova O
    Neoplasma; 2007; 54(6):471-7. PubMed ID: 17949229
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Incidence, sensitivity, and specificity of leukemia-associated phenotypes in acute myeloid leukemia using specific five-color multiparameter flow cytometry.
    Al-Mawali A; Gillis D; Hissaria P; Lewis I
    Am J Clin Pathol; 2008 Jun; 129(6):934-45. PubMed ID: 18480011
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunophenotypic differences between diagnosis and relapse in childhood AML: Implications for MRD monitoring.
    Langebrake C; Brinkmann I; Teigler-Schlegel A; Creutzig U; Griesinger F; Puhlmann U; Reinhardt D
    Cytometry B Clin Cytom; 2005 Jan; 63(1):1-9. PubMed ID: 15624201
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Detection of minimal residual disease in B lineage acute lymphoblastic leukemia by 4-color flow cytometry].
    Liu YR; Wang H; Chang Y; Cheng YF; Fu JY; Zhang LP; Liu GL; Chen SS
    Zhonghua Xue Ye Xue Za Zhi; 2005 Jun; 26(6):327-31. PubMed ID: 16185473
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Quantification of minimal residual disease by multiparameter flow cytometry in acute myeloid leukemia. From diagnosis to prognosis].
    Kern W; Haferlach T
    Med Klin (Munich); 2005 Jan; 100(1):54-9. PubMed ID: 15654545
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The use of receiver operating characteristic analysis for detection of minimal residual disease using five-color multiparameter flow cytometry in acute myeloid leukemia identifies patients with high risk of relapse.
    Al-Mawali A; Gillis D; Lewis I
    Cytometry B Clin Cytom; 2009 Mar; 76(2):91-101. PubMed ID: 18727068
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Analysis of immunophenotype and leukemia associated immunophenotype in 610 patients with acute myeloid leukemia].
    Liu YR; Wang YZ; Chen SS; Chang Y; Fu JY; Li LD; Wang H; Yu H; Jiang B; Huang XJ
    Zhonghua Xue Ye Xue Za Zhi; 2007 Nov; 28(11):731-6. PubMed ID: 18457262
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pattern associated leukemia immunophenotypes and measurable disease detection in acute myeloid leukemia or myelodysplastic syndrome with mutated NPM1.
    Zhou Y; Moon A; Hoyle E; Fromm JR; Chen X; Soma L; Salipante SJ; Wood BL; Wu D
    Cytometry B Clin Cytom; 2019 Jan; 96(1):67-72. PubMed ID: 30417521
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Immunophenotyping in acute leukemia: detection of minimal residual disease].
    Pálóczi K; Nahajevszky S; Jakab K; Regéczy N; Gopcsa L; László E; Földi J
    Orv Hetil; 2000 Nov; 141(46):2487-92. PubMed ID: 11126681
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The role of multiparameter flow cytometry for detection of minimal residual disease in acute myeloid leukemia.
    Al-Mawali A; Gillis D; Lewis I
    Am J Clin Pathol; 2009 Jan; 131(1):16-26. PubMed ID: 19095561
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunophenotypic Detection of Measurable Residual (Stem Cell) Disease Using LAIP Approach in Acute Myeloid Leukemia.
    Zeijlemaker W; Kelder A; Cloos J; Schuurhuis GJ
    Curr Protoc Cytom; 2019 Dec; 91(1):e66. PubMed ID: 31763792
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HLA-DRneg patients without acute promyelocytic leukemia show distinct immunophenotypic, genetic, molecular, and cytomorphologic characteristics compared to acute promyelocytic leukemia.
    Oelschlaegel U; Mohr B; Schaich M; Schäkel U; Kroschinsky F; Illmer T; Ehninger G; Thiede C
    Cytometry B Clin Cytom; 2009 Sep; 76(5):321-7. PubMed ID: 19291801
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of complete disease remission in acute myeloid leukemia: a prospective study based on cytomorphology, interphase fluorescence in situ hybridization, and immunophenotyping during follow-up in patients with acute myeloid leukemia.
    Bacher U; Kern W; Schoch C; Schnittger S; Hiddemann W; Haferlach T
    Cancer; 2006 Feb; 106(4):839-47. PubMed ID: 16419072
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.